Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | EVP, Chief Legal Officer | December 14, 2023 | December 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date December 14, 2023 · Filed December 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,233 |
Ending reported balance
After 2023-12-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-12-14 · Exercise / conversion · Acquired 2,100 · Balance 13,933 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax common stock. Row 2 · 2023-12-14 · Tax withholding · Disposed 700 · Balance 13,233 F2: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Exercise / conversion · Disposed 2,100 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax common stock. F3: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax common stock.
F2: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs.
F3: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2021 Filed Feb 3, 2021 22:37 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 394 | $27.00 | $10,638.00 |
DisclosureSEC source: 0001209191-21-007378 · doc4.xml · nonDerivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 6,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063833 · doc4.xml · derivative · entry 2 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Underlying: Common Stock · 6,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 12,700 | $0.00 Strike: $129.70 | $0.00 |
DisclosureSEC source: 0001209191-20-063833 · doc4.xml · derivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2030-12-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 14, 2020 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,574 | $109.28 | $172,000.90 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 16 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.89 to $109.45, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,419 | $108.39 | $370,586.44 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 15 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,849 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.87 to $108.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 7,061 | $107.30 | $757,643.18 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 14 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,268 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.82 to $107.80, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,975 | $106.18 | $634,436.85 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 13 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.73 to $106.72, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,750 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · derivative · entry 17 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,250 Underlying: Common Stock · 24,750 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 545.86 | $117.07 | $63,901.43 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 12 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,304 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.61 to $117.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 941.12 | $116.08 | $109,242.39 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 11 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.61 to $116.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 992.48 | $115.23 | $114,365.06 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 10 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,791 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.61 to $115.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 396.99 | $113.81 | $45,182.74 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 9 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,783 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.61 to $114.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 719.55 | $113.02 | $81,326.42 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 8 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,180 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.61 to $113.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 213.38 | $111.92 | $23,882.26 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 7 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,900 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.61 to $112.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,319.68 | $110.97 | $257,423.70 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 6 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,113 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.61 to $111.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 8,051.5 | $109.98 | $885,495.11 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 5 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,433 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.61 to $110.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 6,594.79 | $109.07 | $719,281.22 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 4 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,485 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.61 to $109.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,701.71 | $108.20 | $400,514.66 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 3 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,079 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.61 to $108.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 272.93 | $107.22 | $29,263.75 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 2 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,781 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.61 to $107.60, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:30 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 24,750 | $5.95 | $147,262.50 |
DisclosureSEC source: 0001209191-20-052527 · doc4.xml · nonDerivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052367 · doc4.xml · derivative · entry 6 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,946 Underlying: Common Stock · 3,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 30,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052367 · doc4.xml · derivative · entry 5 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested one (1) year from the September 26, 2019 grant date (the "Grant Date"), subject to continued employment with the Company through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested one (1) year from the September 26, 2019 grant date (the "Grant Date"), subject to continued employment with the Company through the vesting date. Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,919 | $113.56 | $217,921.64 |
DisclosureSEC source: 0001209191-20-052367 · doc4.xml · nonDerivative · entry 4 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,304 Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052367 · doc4.xml · nonDerivative · entry 3 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 14,925 | $113.56 | $1,694,883.00 |
DisclosureSEC source: 0001209191-20-052367 · doc4.xml · nonDerivative · entry 2 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 30,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052367 · doc4.xml · nonDerivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 21:29 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-20-048421 · doc4.xml · derivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-04-17 F1 · derivative.exercise_date: On April 17, 2020, the reporting person was granted an option to purchase 125,000 shares of common stock of Novavax, Inc. (the "Company") pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares will vest on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,328 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 18 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,671 Underlying: Common Stock · 8,328 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,322 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 17 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,677 Underlying: Common Stock · 13,322 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,952 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 16 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,298 Underlying: Common Stock · 1,952 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Vesting of the shares subject to this option grant is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested or will vest if, at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock meets or exceeds $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 393 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 15 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394 Underlying: Common Stock · 393 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,249 | $0.00 Strike: $99.80 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 14 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,249 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the March 15, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,499 | $0.00 Strike: $91.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 13 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,499 shares Expires 2024-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the June 12, 2014 grant date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,499 | $0.00 Strike: $36.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 12 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,499 shares Expires 2023-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $50.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · derivative · entry 11 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 10, 2011 grant date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 21,648 | $144.79 | $3,134,413.92 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 10 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275 F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.30 to $145.17, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 24,594 | $143.92 | $3,539,568.48 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 9 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,923 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.30 to $144.29, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 8,328 | $46.00 | $383,088.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 8 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 13,322 | $27.60 | $367,687.20 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 7 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,952 | $27.00 | $52,704.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 6 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 393 | $27.00 | $10,611.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 5 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 11,249 | $99.80 | $1,122,650.20 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 4 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 2,499 | $91.00 | $227,409.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 3 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 7,499 | $36.60 | $274,463.40 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 2 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:51 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078318 · tm2023761-1_4.xml · derivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:38 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 99,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001104659-20-078293 · tm2023760-3_4.xml · derivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 99,000 shares Expires 2029-09-26 F1 · date: This option award was previously reported based on having been approved by the issuer's board of directors on September 26, 2019, but such award was subject to shareholder approval of an increase in the number of shares available for issuance under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). Such shareholder approval was received on June 25, 2020. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the September 26, 2019 grant date and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:35 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to buy) · Derivative | 5,462 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030893 · doc4.xml · derivative · entry 6 Herrmann John A III · CIK 0001610928 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787 Underlying: Common Stock · 5,462 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three years. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:35 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to buy) · Derivative | 7,499 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001209191-20-030893 · doc4.xml · derivative · entry 5 Herrmann John A III · CIK 0001610928 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,499 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option grant under the Novavax, Inc. 2005 Stock Incentive Plan, as amended, vested in four equal annual installments on the first four anniversaries of the March 1, 2012 grant date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:35 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,462 | $49.44 | $270,041.28 |
DisclosureSEC source: 0001209191-20-030893 · doc4.xml · nonDerivative · entry 4 Herrmann John A III · CIK 0001610928 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.